Genmab announced that the European Medicines Agency’s, or EMA, Committee for Medicinal Products for Human Use, or CHMP, has adopted an opinion recommending the granting of conditional marketing authorization of epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, as a monotherapy for the treatment of adult patients with relapsed or refractory, or R/R, follicular lymphoma after two or more lines of systemic therapy. The final European Commission decision on this indication for epcoritamab is anticipated later this year.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
- Genmab Completes Share Buy-back Program Early
- Completion of Share Buy-back Program
- FDA Approves Genmab’s Innovative Lymphoma Treatment
- FDA grants second approval for EPKINLY in r/r follicular lymphoma
Questions or Comments about the article? Write to editor@tipranks.com